Navigation Links
UNC receives $8.5 million for new public health preparedness research center
Date:10/9/2008

CHAPEL HILL The North Carolina Institute for Public Health has been awarded an $8.5 million, five-year grant to create a new research center focused on helping protect the state from a wide range to disasters and threats.

The institute, part of the University of North Carolina at Chapel Hill Gillings School of Global Public Health, was selected by the Centers for Disease Control and Prevention (CDC) to head up one of seven new Preparedness and Emergency Response Research Centers.

The new center will be known as the North Carolina Public Health Preparedness Systems Research Center. Edward L. Baker, M.D., the institute's director and professor of health policy and management in the public health school, was principal investigator of the grant proposal.

The center will focus on conducting research related to public health preparedness and emergency response in North Carolina. Researchers will evaluate disease surveillance and reporting systems, emergency alerting systems, regional response systems and the effects of health department accreditation on preparedness and response capacities.

"What will come out of this center will improve the quality of preparedness and response to all hazards, from hurricanes to contagious diseases to suspected terroristic acts," Baker said. "I believe one of the reasons we secured the grant is that North Carolina is seen as a laboratory for practice research due to its innovative public health preparedness surveillance and response systems."

Several state leaders were involved in helping bring the center to North Carolina, including State Health Director Dr. Leah Devlin and U.S. Sen. Richard Burr.

"Being prepared for any hazard is central to the public health mission in North Carolina," Devlin said. "Clearly evaluating our state and local efforts and answering critical research questions will help us to continually strengthen our system of preparedness and response."

'/>"/>
Contact: Patric Lane
patric_lane@unc.edu
919-962-8596
University of North Carolina at Chapel Hill
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
2. CleveMed Receives $1.23 Million in NIH Funding to Develop a System to Augment Deep Brain Stimulation Programming in Parkinsons Disease
3. DxTech Receives Development Funding
4. Texas Health Resources Receives Grant From Robert Wood Johnson Foundation to Support Prevention of Family Violence
5. MedPlexus Electronic Health Record Receives 08 CCHIT Certification
6. Herley New England Receives Additional $1.3 Million Contract Award from Lockheed Martin for the Multi-Mission Helicopter
7. Updated MD-CARE Act Receives Final Congressional Approval
8. Diabetes Research and Awareness Receives Big Boost Thanks to Generous Gift from Thomas McInerney
9. Digirad Corporation Receives FDA 510(k) Clearance for nSPEED(R) Reconstruction Software for Improved Image Quality in Less Time With Less Radiation
10. Partnership for Peak Healthcare Performance Receives Grant from Aetna Foundation to Improve Area Diabetes Care
11. Freedom Meditech Receives JumpStart Investment
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Mesa Labs Increases Quarterly Dividend 61255 1Neogen to Ring NASDAQs Closing Bell 14815 1Neogen to Ring NASDAQs Closing Bell 14815 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 1Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 3